Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KCNJ8 antisense RNA 1 (KCNJ8-AS1) is an antisense long non-coding RNA gene located in the human genome. It is transcribed from the opposite DNA strand of the KCNJ8 locus. KCNJ8-AS1 belongs to the class of lncRNAs, a group of regulatory RNA molecules exceeding 200 nucleotides in length, and is thought to regulate the expression of its sense gene, KCNJ8 (Kir6.1), which encodes an ATP-sensitive potassium channel involved in the regulation of vascular tone, cardiac electrophysiology, and linked to cardiac disorders such as cardiomyopathy and atrial fibrillation. The major biological role of KCNJ8-AS1 is gene expression regulation, possibly through modulation of KCNJ8 mRNA transcription, stability, or epigenetic status, as described for antisense lncRNAs in the literature. KCNJ8-AS1 is not a protein-coding gene nor a classical therapeutic target such as a receptor or enzyme, and no drugs are currently known to interact with it directly.
Not applicable. lncRNAs regulate gene expression epigenetically or via RNA-RNA interactions rather than by direct binding of small molecules or drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KCNJ8 antisense RNA 1 (KCNJ8-AS1).